• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过针对恶性神经胶质瘤中 IGF2BP3 诱导的 NETosis 来克服溶瘤单纯疱疹病毒治疗的耐药性。

Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma.

机构信息

Department of Pharmacology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.

Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.

出版信息

Nat Commun. 2024 Jan 2;15(1):131. doi: 10.1038/s41467-023-44576-2.

DOI:10.1038/s41467-023-44576-2
PMID:38167409
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10762148/
Abstract

Oncolytic virotherapy holds promise for cancer treatment, but the factors determining its oncolytic activity remain unclear. Neutrophil extracellular traps (NETs) are associated with cancer progression, yet their formation mechanism and role in oncolytic virotherapy remain elusive. In this study, we demonstrate that, in glioma, upregulation of IGF2BP3 enhances the expression of E3 ubiquitin protein ligase MIB1, promoting FTO degradation via the ubiquitin-proteasome pathway. This results in increased m6A-mediated CSF3 release and NET formation. Oncolytic herpes simplex virus (oHSV) stimulates IGF2BP3-induced NET formation in malignant glioma. In glioma models in female mice, a BET inhibitor enhances the oncolytic activity of oHSV by impeding IGF2BP3-induced NETosis, reinforcing virus replication through BRD4 recruitment with the CDK9/RPB-1 complex to HSV gene promoters. Our findings unveil the regulation of m6A-mediated NET formation, highlight oncolytic virus-induced NETosis as a critical checkpoint hindering oncolytic potential, and propose targeting NETosis as a strategy to overcome resistance in oncolytic virotherapy.

摘要

溶瘤病毒治疗在癌症治疗中具有广阔的前景,但决定其溶瘤活性的因素仍不清楚。中性粒细胞胞外诱捕网(NETs)与癌症的进展有关,但它们的形成机制及其在溶瘤病毒治疗中的作用仍不清楚。在这项研究中,我们证明在神经胶质瘤中,IGF2BP3 的上调增强了 E3 泛素蛋白连接酶 MIB1 的表达,通过泛素-蛋白酶体途径促进 FTO 的降解。这导致 m6A 介导的 CSF3 释放和 NET 形成增加。溶瘤单纯疱疹病毒(oHSV)刺激恶性神经胶质瘤中 IGF2BP3 诱导的 NET 形成。在雌性小鼠的神经胶质瘤模型中,BET 抑制剂通过阻止 IGF2BP3 诱导的 NET 细胞凋亡来增强 oHSV 的溶瘤活性,通过 BRD4 与 CDK9/RPB-1 复合物招募到 HSV 基因启动子,增强病毒复制。我们的研究结果揭示了 m6A 介导的 NET 形成的调控,强调了溶瘤病毒诱导的 NET 细胞凋亡作为阻碍溶瘤潜能的关键检查点,并提出了将 NET 细胞凋亡作为克服溶瘤病毒治疗中耐药性的一种策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c56/10762148/1ffff9c7eb1b/41467_2023_44576_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c56/10762148/94f77a276f78/41467_2023_44576_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c56/10762148/0faee3816b33/41467_2023_44576_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c56/10762148/0eca7c26bce9/41467_2023_44576_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c56/10762148/206d049c56b4/41467_2023_44576_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c56/10762148/e47a2c13f6bb/41467_2023_44576_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c56/10762148/2440163b558d/41467_2023_44576_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c56/10762148/b632da70237d/41467_2023_44576_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c56/10762148/1ffff9c7eb1b/41467_2023_44576_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c56/10762148/94f77a276f78/41467_2023_44576_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c56/10762148/0faee3816b33/41467_2023_44576_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c56/10762148/0eca7c26bce9/41467_2023_44576_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c56/10762148/206d049c56b4/41467_2023_44576_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c56/10762148/e47a2c13f6bb/41467_2023_44576_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c56/10762148/2440163b558d/41467_2023_44576_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c56/10762148/b632da70237d/41467_2023_44576_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c56/10762148/1ffff9c7eb1b/41467_2023_44576_Fig8_HTML.jpg

相似文献

1
Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma.通过针对恶性神经胶质瘤中 IGF2BP3 诱导的 NETosis 来克服溶瘤单纯疱疹病毒治疗的耐药性。
Nat Commun. 2024 Jan 2;15(1):131. doi: 10.1038/s41467-023-44576-2.
2
Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application.溶瘤单纯疱疹病毒治疗恶性脑胶质瘤:成功临床应用的当前方法。
Expert Opin Biol Ther. 2019 Aug;19(8):845-854. doi: 10.1080/14712598.2019.1614557. Epub 2019 May 13.
3
Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.免疫细胞在单纯疱疹病毒溶瘤疗法治疗脑胶质瘤中的意义。
Brain Tumor Pathol. 2022 Apr;39(2):57-64. doi: 10.1007/s10014-022-00431-8. Epub 2022 Apr 6.
4
Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.铜螯合增强了溶瘤单纯疱疹病毒的抗肿瘤疗效和全身递送。
Clin Cancer Res. 2012 Sep 15;18(18):4931-41. doi: 10.1158/1078-0432.CCR-12-0697. Epub 2012 Jul 2.
5
Tumour-specific triple-regulated oncolytic herpes virus to target glioma.靶向胶质瘤的肿瘤特异性三重调控溶瘤疱疹病毒
Oncotarget. 2016 May 10;7(19):28658-69. doi: 10.18632/oncotarget.8637.
6
Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration.糖基化-PEG 掩蔽的溶瘤病毒全身给药增强了抗肿瘤免疫病毒疗法的靶向性,并调节了 T 和 NK 细胞浸润。
Theranostics. 2023 Oct 2;13(15):5452-5468. doi: 10.7150/thno.87498. eCollection 2023.
7
Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.溶瘤单纯疱疹病毒 γ34.5 缺失对神经胶质瘤干细胞复制的限制。
J Virol. 2018 Jul 17;92(15). doi: 10.1128/JVI.00246-18. Print 2018 Aug 1.
8
HSV-1-induced N6-methyladenosine reprogramming via ICP0-mediated suppression of METTL14 potentiates oncolytic activity in glioma.单纯疱疹病毒 1 诱导的 N6-甲基腺苷重编程通过 ICP0 介导的 METTL14 抑制增强胶质母细胞瘤的溶瘤活性。
Cell Rep. 2024 Oct 22;43(10):114756. doi: 10.1016/j.celrep.2024.114756. Epub 2024 Sep 25.
9
Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.联合使用鲁索替尼和溶瘤单纯疱疹病毒使耐药 MPNST 对病毒治疗敏感。
Cancer Immunol Res. 2018 Dec;6(12):1499-1510. doi: 10.1158/2326-6066.CIR-18-0014. Epub 2018 Oct 23.
10
Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models.组蛋白去乙酰化酶抑制剂帕比司他增强溶瘤单纯疱疹病毒联合 PD-1/PD-L1 阻断在胶质瘤和鳞状细胞癌模型中的治疗疗效。
Viruses. 2022 Dec 15;14(12):2796. doi: 10.3390/v14122796.

引用本文的文献

1
Comment on IGF2BP3 promotes the proliferation and cisplatin resistance of bladder cancer by enhancing the mRNA stability of CDK6 in an mA dependent manner.评论:胰岛素样生长因子2 mRNA结合蛋白3通过以N6-甲基腺苷依赖的方式增强细胞周期蛋白依赖性激酶6的mRNA稳定性,促进膀胱癌的增殖和顺铂耐药性。
Int J Biol Sci. 2025 Aug 16;21(12):5284-5286. doi: 10.7150/ijbs.120024. eCollection 2025.
2
Progress in the mechanistic understanding of NETs formation in cancer.癌症中中性粒细胞胞外陷阱形成机制的研究进展
Med Oncol. 2025 Aug 27;42(10):451. doi: 10.1007/s12032-025-03010-x.
3
Resistance to oncolytic virotherapy: Multidimensional mechanisms and therapeutic breakthroughs (Review).

本文引用的文献

1
Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-β activation.化疗期间形成的中性粒细胞胞外陷阱通过 TGF-β 激活赋予治疗抵抗性。
Cancer Cell. 2023 Apr 10;41(4):757-775.e10. doi: 10.1016/j.ccell.2023.03.008.
2
Monocyte-neutrophil entanglement in glioblastoma.胶质母细胞瘤中的单核细胞-中性粒细胞纠结。
J Clin Invest. 2023 Jan 3;133(1):e163451. doi: 10.1172/JCI163451.
3
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
溶瘤病毒疗法的耐药性:多维机制与治疗突破(综述)
Int J Mol Med. 2025 Nov;56(5). doi: 10.3892/ijmm.2025.5612. Epub 2025 Aug 24.
4
CRISPR/Cas9 screening identifies SUV39H2 as a key regulator of oHSV-1 resistance in oral squamous cell carcinoma.CRISPR/Cas9筛选确定SUV39H2是口腔鳞状细胞癌中对oHSV-1耐药性的关键调节因子。
Cell Death Discov. 2025 Aug 23;11(1):402. doi: 10.1038/s41420-025-02702-7.
5
Neutrophil Dynamics in Response to Cancer Therapies.中性粒细胞对癌症治疗的反应动力学
Cancers (Basel). 2025 Aug 7;17(15):2593. doi: 10.3390/cancers17152593.
6
Ginsenoside Rb1 mitigates atherosclerosis in part through modulating FTO-mediated mA RNA modification in NETs-induced endothelial activation.人参皂苷Rb1部分通过调节FTO介导的NETs诱导的内皮细胞活化中的m⁶A RNA修饰来减轻动脉粥样硬化。
Front Pharmacol. 2025 Jul 23;16:1631076. doi: 10.3389/fphar.2025.1631076. eCollection 2025.
7
Shaping viral immunotherapy towards cancer-targeted immunological cell death.将病毒免疫疗法导向癌症靶向性免疫细胞死亡。
Front Oncol. 2025 Jul 8;15:1540397. doi: 10.3389/fonc.2025.1540397. eCollection 2025.
8
Oncolytic virus therapy in hepatocellular carcinoma.肝细胞癌的溶瘤病毒疗法
Oncol Res. 2025 Jun 26;33(7):1593-1610. doi: 10.32604/or.2025.061857. eCollection 2025.
9
Targeting TBK1 potentiates oncolytic virotherapy via amplifying ICAM1-mediated NK cell immunity in chemo-resistant colorectal cancer.靶向TBK1通过增强ICAM1介导的化疗耐药性结直肠癌中的自然杀伤细胞免疫来增强溶瘤病毒疗法。
J Immunother Cancer. 2025 Jun 8;13(6):e011455. doi: 10.1136/jitc-2024-011455.
10
RNA epigenetic modifications as dynamic biomarkers in cancer: from mechanisms to clinical translation.RNA表观遗传修饰作为癌症中的动态生物标志物:从机制到临床转化
Biomark Res. 2025 Jun 7;13(1):81. doi: 10.1186/s40364-025-00794-y.
随机、双盲、安慰剂对照、全球 III 期试验:替莫唑胺联合替莫唑胺治疗晚期黑色素瘤。
J Clin Oncol. 2023 Jan 20;41(3):528-540. doi: 10.1200/JCO.22.00343. Epub 2022 Aug 23.
4
Targeting m6A modification inhibits herpes virus 1 infection.靶向m6A修饰可抑制单纯疱疹病毒1型感染。
Genes Dis. 2021 Feb 22;9(4):1114-1128. doi: 10.1016/j.gendis.2021.02.004. eCollection 2022 Jul.
5
Therapeutic targeting m6A-guided miR-146a-5p signaling contributes to the melittin-induced selective suppression of bladder cancer.靶向 m6A 调控的 miR-146a-5p 信号通路促进蜂毒素选择性抑制膀胱癌。
Cancer Lett. 2022 May 28;534:215615. doi: 10.1016/j.canlet.2022.215615. Epub 2022 Mar 9.
6
Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer.利用溶瘤病毒激发膀胱癌的肿瘤免疫微环境。
Nat Rev Urol. 2021 Sep;18(9):543-555. doi: 10.1038/s41585-021-00483-z. Epub 2021 Jun 28.
7
Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.溶瘤单纯疱疹病毒 1 型 G207 免疫病毒疗法治疗儿科高级别脑胶质瘤。
N Engl J Med. 2021 Apr 29;384(17):1613-1622. doi: 10.1056/NEJMoa2024947. Epub 2021 Apr 10.
8
Macrophages and microglia: the cerberus of glioblastoma.巨噬细胞和小胶质细胞:胶质母细胞瘤的三头犬。
Acta Neuropathol Commun. 2021 Mar 25;9(1):54. doi: 10.1186/s40478-021-01156-z.
9
Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.泛癌症分析免疫细胞浸润鉴定出肺腺癌预后免疫细胞特征评分(ICCS)。
Front Immunol. 2020 Jun 30;11:1218. doi: 10.3389/fimmu.2020.01218. eCollection 2020.
10
Genetic driver mutations introduced in identical cell-of-origin in murine glioblastoma reveal distinct immune landscapes but similar response to checkpoint blockade.在同源细胞起源的鼠胶质母细胞瘤中引入的遗传驱动突变揭示了不同的免疫景观,但对检查点阻断的反应相似。
Glia. 2020 Oct;68(10):2148-2166. doi: 10.1002/glia.23883. Epub 2020 Jul 8.